1
|
Russo D, Travaglino A, Varricchio S, Pace M, Cretella P, Baldo A, Severino A, Picardi M, Mascolo M. Prognostic value of Bcl2 and Bcl6 in primary cutaneous large B-cell lymphoma: A systematic review and meta-analysis. Pathol Res Pract 2022; 232:153812. [PMID: 35220171 DOI: 10.1016/j.prp.2022.153812] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2021] [Revised: 02/10/2022] [Accepted: 02/18/2022] [Indexed: 12/19/2022]
Abstract
AIMS To assess the prognostic value of Bcl2 and Bcl6 in primary cutaneous diffuse large B-cell lymphoma (pcDLBCL), through a systematic review and meta-analysis. METHODS Electronic databases were searched from their inception to April 2021 for studies reporting Bcl2 and Bcl6 expression and survival outcomes in pcDLBCL series. Kaplan-Meier and Cox regression survival analyses with hazard ratio calculation were performed for overall survival (OS), with a significant p-value< 0.05. RESULTS Eight studies with 148 patients were included. OS was significantly decreased in Bcl2-pos itive pcDLBCLs (5-year OS= 52.9 ± 5.2%) compared to Bcl2 negative pcDLBCLs (5-year OS= 86.6 ± 7.2%), with a HR of 4.615 (95% CI, 1.827-11.657; p = 0.001); no significant difference in OS was found between Bcl6-positive pcDLBCLs (5-year OS= 61.3 ± 6.5%) and Bcl6-negative pcDLBCLs (5-year OS= 56.8 ± 7.2%), with a HR of 0.789 (95% CI, 0.462-1.350; p = 0.388). CONCLUSIONS In pcDLBCL, Bcl2 expression is a strong unfavourable prognostic marker; Bcl6 does not seem to be associated with survival instead. Further studies are necessary in this field.
Collapse
Affiliation(s)
- Daniela Russo
- Department of Advanced Biomedical Sciences, Pathology Section, University of Naples "Federico II", Naples, Italy
| | - Antonio Travaglino
- Department of Advanced Biomedical Sciences, Pathology Section, University of Naples "Federico II", Naples, Italy; Gynecopathology and Breast Pathology Unit, Department of Woman's Health Science, Agostino Gemelli University Polyclinic, Rome, Italy
| | - Silvia Varricchio
- Department of Advanced Biomedical Sciences, Pathology Section, University of Naples "Federico II", Naples, Italy
| | - Mirella Pace
- Department of Advanced Biomedical Sciences, Pathology Section, University of Naples "Federico II", Naples, Italy
| | - Pasquale Cretella
- Department of Advanced Biomedical Sciences, Pathology Section, University of Naples "Federico II", Naples, Italy
| | - Antonello Baldo
- Dermatology Section, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy
| | - Alessandro Severino
- Department of Clinical Medicine and Surgery, Hematology Section, University of Naples "Federico II", Naples, Italy
| | - Marco Picardi
- Department of Clinical Medicine and Surgery, Hematology Section, University of Naples "Federico II", Naples, Italy
| | - Massimo Mascolo
- Department of Advanced Biomedical Sciences, Pathology Section, University of Naples "Federico II", Naples, Italy.
| |
Collapse
|
2
|
Abdul Pari AA, Singhal M, Hübers C, Mogler C, Schieb B, Gampp A, Gengenbacher N, Reynolds LE, Terhardt D, Géraud C, Utikal J, Thomas M, Goerdt S, Hodivala-Dilke KM, Augustin HG, Felcht M. Tumor Cell-Derived Angiopoietin-2 Promotes Metastasis in Melanoma. Cancer Res 2020; 80:2586-2598. [PMID: 32303578 DOI: 10.1158/0008-5472.can-19-2660] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Revised: 03/16/2020] [Accepted: 04/14/2020] [Indexed: 01/12/2023]
Abstract
The angiopoietin (Angpt)-TIE signaling pathway controls vascular maturation and maintains the quiescent phenotype of resting vasculature. The contextual agonistic and antagonistic Tie2 ligand ANGPT2 is believed to be exclusively produced by endothelial cells, disrupting constitutive ANGPT1-TIE2 signaling to destabilize the microvasculature during pathologic disorders like inflammation and cancer. However, scattered reports have also portrayed tumor cells as a source of ANGPT2. Employing ISH-based detection of ANGPT2, we found strong tumor cell expression of ANGPT2 in a subset of patients with melanoma. Comparative analysis of biopsies revealed a higher fraction of ANGPT2-expressing tumor cells in metastatic versus primary sites. Tumor cell-expressed Angpt2 was dispensable for primary tumor growth, yet in-depth analysis of primary tumors revealed enhanced intratumoral necrosis upon silencing of tumor cell Angpt2 expression in the absence of significant immune and vascular alterations. Global transcriptional profiling of Angpt2-deficient tumor cells identified perturbations in redox homeostasis and an increased response to cellular oxidative stress. Ultrastructural analyses illustrated a significant increase of dysfunctional mitochondria in Angpt2-silenced tumor cells, thereby resulting in enhanced reactive oxygen species (ROS) production and downstream MAPK stress signaling. Functionally, enhanced ROS in Angpt2-silenced tumor cells reduced colonization potential in vitro and in vivo. Taken together, these findings uncover the hitherto unappreciated role of tumor cell-expressed ANGPT2 as an autocrine-positive regulator of metastatic colonization and validate ANGPT2 as a therapeutic target for a well-defined subset of patients with melanoma. SIGNIFICANCE: This study reveals that tumor cells can be a source of ANGPT2 in the tumor microenvironment and that tumor cell-derived ANGPT2 augments metastatic colonization by protecting tumor cells from oxidative stress.
Collapse
Affiliation(s)
- Ashik Ahmed Abdul Pari
- European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.,Vascular Oncology and Metastasis, German Cancer Research Center, Heidelberg (DKFZ-ZMBH Alliance), Germany
| | - Mahak Singhal
- European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.,Vascular Oncology and Metastasis, German Cancer Research Center, Heidelberg (DKFZ-ZMBH Alliance), Germany
| | - Corinne Hübers
- Vascular Oncology and Metastasis, German Cancer Research Center, Heidelberg (DKFZ-ZMBH Alliance), Germany.,Department of Dermatology, Venerology und Allergology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Carolin Mogler
- Institute of Pathology, Technical University of Munich, Munich, Germany
| | - Benjamin Schieb
- European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.,Vascular Oncology and Metastasis, German Cancer Research Center, Heidelberg (DKFZ-ZMBH Alliance), Germany
| | - Anja Gampp
- European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.,Vascular Oncology and Metastasis, German Cancer Research Center, Heidelberg (DKFZ-ZMBH Alliance), Germany
| | - Nicolas Gengenbacher
- European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.,Vascular Oncology and Metastasis, German Cancer Research Center, Heidelberg (DKFZ-ZMBH Alliance), Germany
| | - Louise E Reynolds
- Center for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Center, London, United Kingdom
| | - Dorothee Terhardt
- Vascular Oncology and Metastasis, German Cancer Research Center, Heidelberg (DKFZ-ZMBH Alliance), Germany
| | - Cyrill Géraud
- European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.,Department of Dermatology, Venerology und Allergology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.,Section of Clinical and Molecular Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Jochen Utikal
- Department of Dermatology, Venerology und Allergology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.,Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Markus Thomas
- Roche Pharma Research and Early Development, Roche Innovation Center Munich, Roche Diagnostics GmbH, Penzberg, Germany
| | - Sergij Goerdt
- European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.,Department of Dermatology, Venerology und Allergology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Kairbaan M Hodivala-Dilke
- Center for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Center, London, United Kingdom
| | - Hellmut G Augustin
- European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. .,Vascular Oncology and Metastasis, German Cancer Research Center, Heidelberg (DKFZ-ZMBH Alliance), Germany.,German Cancer consortium, Heidelberg, Germany
| | - Moritz Felcht
- European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. .,Department of Dermatology, Venerology und Allergology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| |
Collapse
|
3
|
Nicolini G, Forini F, Kusmic C, Iervasi G, Balzan S. Angiopoietin 2 signal complexity in cardiovascular disease and cancer. Life Sci 2019; 239:117080. [PMID: 31756341 DOI: 10.1016/j.lfs.2019.117080] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 11/12/2019] [Accepted: 11/13/2019] [Indexed: 12/12/2022]
Abstract
The angiopoietin signal transduction system is a complex of vascular-specific kinase pathways that plays a crucial role in angiogenesis and maintenance of vascular homeostasis. Angiopoietin1 (Ang1) and 2 (Ang2), the ligand proteins of the pathway, belong to a family of glycoproteins that signal primarily through the transmembrane Tyrosine-kinase-2 receptor. Despite a considerable sequence homology, Ang1 and Ang2 manifest antagonistic effects in pathophysiological conditions. While Ang1 promotes the activation of survival pathways and the stabilization of the normal mature vessels, Ang2 can either favor vessel destabilization and leakage or promote abnormal EC proliferation in a context-dependent manner. Altered Ang1/Ang2 balance has been reported in various pathological conditions in association with inflammation and deregulated angiogenesis. In particular, increased Ang2 levels have been documented in human cancer and cardiovascular disease (CVD), including ischemic myocardial injury, heart failure and other cardiovascular complications secondary to diabetes, chronic renal damage and hypertension. Despite the obvious phenotypic differences, CVD and cancer share some common Ang2-dependent etiopathological mechanisms such as inflammation, epithelial (or endothelial) to mesenchymal transition, and adverse vascular network remodeling. Interestingly, both cancer and CVD are negatively affected by thyroid hormone dyshomeostasis. This review provides an overview of the complex Ang2-dependent signaling involved in CVD and cancer, as well as a survey of the related clinical literature. Moreover, on the basis of recent molecular acquisitions in an experimental model of post ischemic cardiac disease, the putative novel role of the thyroid hormone in the regulation of Ang1/Ang2 balance is also briefly discussed.
Collapse
Affiliation(s)
| | - Francesca Forini
- Institute of Clinical Physiology, CNR, Via G.Moruzzi 1, 56124 Pisa, Italy.
| | - Claudia Kusmic
- Institute of Clinical Physiology, CNR, Via G.Moruzzi 1, 56124 Pisa, Italy.
| | - Giorgio Iervasi
- Institute of Clinical Physiology, CNR, Via G.Moruzzi 1, 56124 Pisa, Italy.
| | - Silvana Balzan
- Institute of Clinical Physiology, CNR, Via G.Moruzzi 1, 56124 Pisa, Italy.
| |
Collapse
|
4
|
Felcht M, Klemke CD, Nicolay JP, Weiss C, Assaf C, Wobser M, Schlaak M, Hillen U, Moritz R, Tantcheva-Poor I, Nashan D, Beyer M, Dippel E, Müller CSL, Sachse MM, Meiss F, Géraud C, Marx A, Goerdt S, Geissinger E, Kempf W. Primär kutanes diffus-großzelliges B-Zell-Lymphom, NOS oder leg type: klinische, morphologische und prognostische Unterschiede. J Dtsch Dermatol Ges 2019; 17:275-286. [PMID: 30920753 DOI: 10.1111/ddg.13773_g] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Accepted: 09/04/2018] [Indexed: 11/29/2022]
Affiliation(s)
- Moritz Felcht
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg und Exzellenzzentrum Dermatologie des Landes Baden-Württemberg, Mannheim, Deutschland.,European Center of Angioscience, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland
| | - Claus-Detlev Klemke
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg und Exzellenzzentrum Dermatologie des Landes Baden-Württemberg, Mannheim, Deutschland.,Hautklinik, Städtisches Klinikum Karlsruhe, Akademisches Lehrkrankenhaus der Universität Freiburg, Karlsruhe, Deutschland
| | - Jan Peter Nicolay
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg und Exzellenzzentrum Dermatologie des Landes Baden-Württemberg, Mannheim, Deutschland
| | - Christel Weiss
- Abteilung für Medizinische Statistik, Ruprecht-Karls-Universität Heidelberg, Mannheim, Deutschland
| | - Chalid Assaf
- Klinik für Dermatologie und Venerologie, Klinikum Krefeld, Krefeld, Deutschland
| | - Marion Wobser
- Klinik für Dermatologie, Venerologie und Allergologie, Julius-Maximilians- Universität, Würzburg, Deutschland
| | - Max Schlaak
- Klinik für Dermatologie und Venerologie, Universität zu Köln, Köln, Deutschland
| | - Uwe Hillen
- Klinik für Dermatologie und Hauttumorzentrum, Universitätsklinikum Essen-Duisburg, Essen-Duisburg, Deutschland
| | - Rose Moritz
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum Bochum, Deutschland.,Universitäts- und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum Halle (Saale)
| | | | | | - Marc Beyer
- Hauttumorcentrum Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland
| | - Edgar Dippel
- Hautklinik, Klinikum Ludwigshafen, Ludwigshafen, Deutschland
| | - Cornelia Sigrid Lissi Müller
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsklinikum des Saarlandes, Homburg/Saar, Deutschland
| | - Michael Max Sachse
- Klinik für Dermatologie, Allergologie und Phlebologie, Klinikum Bremerhaven, Bremerhaven, Deutschland.,Hautklinik Bremen, Deutschland
| | - Frank Meiss
- Klinik für Dermatologie und Venerologie, Universitätsklinikum Freiburg, Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Deutschland
| | - Cyrill Géraud
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg und Exzellenzzentrum Dermatologie des Landes Baden-Württemberg, Mannheim, Deutschland.,European Center of Angioscience, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland
| | - Alexander Marx
- Pathologisches Institut, Ruprecht-Karls-Universität Heidelberg, Mannheim, Deutschland
| | - Sergij Goerdt
- Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg und Exzellenzzentrum Dermatologie des Landes Baden-Württemberg, Mannheim, Deutschland.,European Center of Angioscience, Medizinische Fakultät Mannheim, Universität Heidelberg, Mannheim, Deutschland
| | - Eva Geissinger
- Institut für Pathologie, Julius-Maximilians-Universität, Würzburg, Deutschland
| | - Werner Kempf
- Kempf und Pfaltz, Histologische Diagnostik, Zürich, Schweiz.,Dermatologische Klinik, Universitätsspital Zürich, Zürich, Schweiz
| |
Collapse
|
5
|
Felcht M, Klemke CD, Nicolay JP, Weiss C, Assaf C, Wobser M, Schlaak M, Hillen U, Moritz R, Tantcheva-Poor I, Nashan D, Beyer M, Dippel E, Müller CSL, Sachse MM, Meiss F, Géraud C, Marx A, Goerdt S, Geissinger E, Kempf W. Primary cutaneous diffuse large B-cell lymphoma, NOS and leg type: Clinical, morphologic and prognostic differences. J Dtsch Dermatol Ges 2019; 17:275-285. [PMID: 30851152 DOI: 10.1111/ddg.13773] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2018] [Accepted: 09/04/2018] [Indexed: 11/27/2022]
Abstract
BACKGROUND AND OBJECTIVES Primary cutaneous diffuse large B-cell lymphoma, NOS (PCLBCL/NOS) is a rare PCLBCL. Only few data are available for this tumor. The aim of this study was to identify clinical and/or immunohistochemical markers (in addition to Bcl-2) that characterize PCLBCL/NOS, assist in differentiating it from PCLBCL, leg type (PCLBCL/LT) and help to assess the clinical course/prognosis. PATIENTS AND METHODS Bcl-2- PCLBCL/NOS) cases (n = 14 were compared with Bcl-2+ PCLBCL/LT cases (n = 29). RESULTS PCLBCL/NOS patients were younger, predominantly male and had better survival rates than patients with PCLBCL/LT. Patients with PCLBCL/NOS presented more often with larger plaques limited to one or two contiguous body regions, whereas PCLBCL/LT cases often presented with disseminated lesions. Neoplastic cells had a higher proliferation rate (Ki67) in PCLBCL/LT patients. The tumor microenvironment of PCLBCL/NOS had a more prominent CD3+ infiltrate. Overall survival data for the whole cohort (n = 37) revealed that female gender and Bcl-2 expression correlated with a worse survival rate. Bcl-6 expression and centroblastic subtype correlated with better outcomes. None of the other markers studied (e.g. GCB/non-GCB subtype) correlated with survival rate. CONCLUSIONS PCLBCL/NOS and PCLBCL/LT differ in their clinical behavior and outcomes. Bcl-2 still seems to be the best marker for discriminating between these two subgroups. Bcl-2, female gender and Bcl-6 represent prognostic markers for PCLBCL.
Collapse
Affiliation(s)
- Moritz Felcht
- Department of Dermatology, Venereology and Allergy, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University and Centre of Excellence of Dermatology of Baden-Württemberg, Mannheim, Germany.,European Center of Angioscience, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
| | - Claus-Detlev Klemke
- Department of Dermatology, Venereology and Allergy, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University and Centre of Excellence of Dermatology of Baden-Württemberg, Mannheim, Germany.,Hautklinik, Städtisches Klinikum Karlsruhe, Akademisches Lehrkrankenhaus der Universität Freiburg, Karlsruhe, Germany
| | - Jan Peter Nicolay
- Department of Dermatology, Venereology and Allergy, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University and Centre of Excellence of Dermatology of Baden-Württemberg, Mannheim, Germany
| | - Christel Weiss
- Department of Medical Statistics, Ruprecht-Karls-University of Heidelberg, Mannheim, Germany
| | - Chalid Assaf
- Department of Dermatology, Hospital of Krefeld, Krefeld, Germany
| | - Marion Wobser
- Department of Dermatology, Venereology and Allergy, Julius-Maximilians-University, Würzburg, Germany
| | - Max Schlaak
- Department of Dermatology, University of Cologne, Cologne, Germany
| | - Uwe Hillen
- Department of Dermatology and Skin Tumor Center, University Hospital Essen-Duisburg, Essen-Duisburg, Germany
| | - Rose Moritz
- Department of Dermatology, Venereology and Allergy, University Hospital Bochum, Bochum, Germany.,Department of Dermatology and Venereology, University Hospital and Martin-Luther-University of Halle-Wittenberg, Halle (Saale), Germany
| | | | - Dorothee Nashan
- Department of Dermatology, Hospital of Dortmund, Dortmund, Germany
| | - Marc Beyer
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité -Universitätsmedizin Berlin, Berlin, Germany
| | - Edgar Dippel
- Department of Dermatology, Hospital of Ludwigshafen, Ludwigshafen, Germany
| | | | - Michael Max Sachse
- Department of Dermatology, Allergy and Phlebology, Hospital of Bremerhaven, Bremerhaven, Germany.,Department of Dermatology, Hospital of Bremen, Bremen, Germany
| | - Frank Meiss
- Department of Dermatology and Venereology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
| | - Cyrill Géraud
- Department of Dermatology, Venereology and Allergy, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University and Centre of Excellence of Dermatology of Baden-Württemberg, Mannheim, Germany.,European Center of Angioscience, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
| | - Alexander Marx
- Department of Pathology, Ruprecht-Karls-University of Heidelberg, Mannheim, Germany
| | - Sergij Goerdt
- Department of Dermatology, Venereology and Allergy, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University and Centre of Excellence of Dermatology of Baden-Württemberg, Mannheim, Germany.,European Center of Angioscience, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany
| | - Eva Geissinger
- Institute of Pathology, Julius-Maximilians-University, Würzburg, Germany
| | - Werner Kempf
- Kempf and Pfaltz, Histologische Diagnostik, Zurich, Switzerland.,Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| |
Collapse
|
6
|
Nicolay JP, Felcht M, Schledzewski K, Goerdt S, Géraud C. Sézary syndrome: old enigmas, new targets. J Dtsch Dermatol Ges 2016; 14:256-64. [DOI: 10.1111/ddg.12900] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Affiliation(s)
- Jan P. Nicolay
- Department of Dermatology, Venereology and Allergology; University Medical Center and Medical Faculty Mannheim; University of Heidelberg; Mannheim Germany
- Department of Immunogenetics; German Cancer Research Center; Heidelberg Germany
| | - Moritz Felcht
- Department of Dermatology, Venereology and Allergology; University Medical Center and Medical Faculty Mannheim; University of Heidelberg; Mannheim Germany
| | - Kai Schledzewski
- Department of Dermatology, Venereology and Allergology; University Medical Center and Medical Faculty Mannheim; University of Heidelberg; Mannheim Germany
| | - Sergij Goerdt
- Department of Dermatology, Venereology and Allergology; University Medical Center and Medical Faculty Mannheim; University of Heidelberg; Mannheim Germany
| | - Cyrill Géraud
- Department of Dermatology, Venereology and Allergology; University Medical Center and Medical Faculty Mannheim; University of Heidelberg; Mannheim Germany
| |
Collapse
|
7
|
Nicolay JP, Felcht M, Schledzewski K, Goerdt S, Géraud C. Sézary-Syndrom: von ungelösten Fragen zu neuen Therapieansätzen. J Dtsch Dermatol Ges 2016. [DOI: 10.1111/ddg.12900_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Jan P. Nicolay
- Klinik für Dermatologie, Venerologie und Allergologie; Universitätsklinikum Mannheim und Medizinische Fakultät Mannheim der Universität Heidelberg; Mannheim Deutschland
- Abteilung für Immungenetik; Deutsches Krebsforschungszentrum; Heidelberg Deutschland
| | - Moritz Felcht
- Klinik für Dermatologie, Venerologie und Allergologie; Universitätsklinikum Mannheim und Medizinische Fakultät Mannheim der Universität Heidelberg; Mannheim Deutschland
| | - Kai Schledzewski
- Klinik für Dermatologie, Venerologie und Allergologie; Universitätsklinikum Mannheim und Medizinische Fakultät Mannheim der Universität Heidelberg; Mannheim Deutschland
| | - Sergij Goerdt
- Klinik für Dermatologie, Venerologie und Allergologie; Universitätsklinikum Mannheim und Medizinische Fakultät Mannheim der Universität Heidelberg; Mannheim Deutschland
| | - Cyrill Géraud
- Klinik für Dermatologie, Venerologie und Allergologie; Universitätsklinikum Mannheim und Medizinische Fakultät Mannheim der Universität Heidelberg; Mannheim Deutschland
| |
Collapse
|